Skip to content

Study of Ashwagandha (Withania somnifera) in stress disorder

Efficacy And Safety of KSM66 Ashwagandha (Withania somnifera) In Stress Disorders in Healthy Adults: A Prospective, Randomized, Double-Blind Placebo Controlled Study.

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2016/10/007353
Enrollment
50
Registered
2016-10-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Sponsors

Shri Kartikeya Pharma
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Adult male or female patients aged between 18 â?? 60 years of age 2.Patients with routine work stress 3.Patients stress disorders characterized with difficulty in concentration, physical exhaustion, anxiety, restlessness, insomnia, headache, fatigue, loss of appetite, phobia, sweating, mental confusion etc. 4.Patients with Perceived Stress Scale (PSS) score more than or equal to 20 (high stress level) 5.Body mass index between 25 and 39.9 kg/m2

Exclusion criteria

Exclusion criteria: 1.Participants who have a diagnosable eating disorder will also be excluded since intentional restriction of eating and binge eating/overeating could increase the variability of the data 2.Currently (in the past three months) attending a weight loss program 3.Underlying genetic or endocrine cause for weight gain 4.Medications known to affect weight (corticosteroids, antidepressants, anti-psychotics, mood stabilizers, and anti-epileptic medications) 5.History of Alcohol or smoking abuse 6.Have clinically significant acute unstable hepatic, renal, cardiovascular or respiratory disease that will prevent participation in the study 7.Patients with depressive episode, panic disorder, social phobia, obsessive-compulsory disorder; alcohol dependency; schizophrenia and mania 8.Patients with post traumatic disorder 9.Have an established practice of meditation for three or more months 10.Pregnant and lactating women 11.Subjects with known hypersensitivity to Ashwagandha 12.Participation in other clinical trials during previous 3 months 13.Any clinical condition, according to the investigator which does not allow safe fulfillment of clinical trial protocol

Design outcomes

Primary

MeasureTime frame
Improvement from baseline in Perceived Stress Scale score (PSS) after 8 weeks.Timepoint: 8 weeks

Secondary

MeasureTime frame
Body mass index (BMI) and absolute and percentage weight loss will be compared.Timepoint: 8 weeks;Change from baseline in vital signsTimepoint: 8 weeks;Change in WeightTimepoint: baseline, week 4 and week 8;Improvement from baseline in the score for Oxford Happiness Scale after therapyTimepoint: baseline, week 4 and week 8;Improvement from baseline in urine cortisol levelTimepoint: baseline, week 4 and week 8

Countries

India

Contacts

Public ContactDr Dnyanraj Choudhary

Atur Sangtani

dr.dnyanrajc@yahoo.co.in9823217423

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026